|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Other interest bearing deposits | ||||||||||||||||||||
| Available for sale ("AFS") securities, at fair value (amortized cost of $183,152, net of allowance for credit losses of $0 at September 30, 2023) | ||||||||||||||||||||
| Held to maturity ("HTM") securities, at amortized cost, net of allowance for credit losses of $0 at September 30, 2023 | ||||||||||||||||||||
| Available-for-sale ("AFS") securities, at fair value (amortized cost of $145,282, net of allowance for credit losses of $0 at June 30, 2026 and amortized cost of $151,618, net of allowance for credit losses of $0 at December 31, 2025) | ||||||||||||||||||||
| Held-to-maturity ("HTM") securities, at amortized cost (fair value of $61,481, net of allowance for credit losses of $0 at June 30, 2026 and fair value of $64,117, net of allowance for credit losses of $0 at December 31, 2025) | ||||||||||||||||||||
| Equity investments | ||||||||||||||||||||
| Other investments | ||||||||||||||||||||
| Loans receivable | ||||||||||||||||||||
| Allowance for credit losses | ||||||||||||||||||||
| Loans receivable, net | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| Mortgage servicing rights, net | ||||||||||||||||||||
| Office properties and equipment, net | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Intangible assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Foreclosed and repossessed assets, net | ||||||||||||||||||||
| Bank owned life insurance ("BOLI") | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| Liabilities and Stockholders’ Equity | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Federal Home Loan Bank (“FHLB”) advances | ||||||||||||||||||||
| Other borrowings | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ Equity: | ||||||||||||||||||||
| Common stock—$0.01 par value, authorized 30,000,000; 9,650,231 and 9,617,245 shares issued and outstanding, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
Loading...
